Currently, the IL-15 fusion protein ALT-803, in combination with rituximab, is being tested in a clinical trial in patients with indolent B cell non-Hodgkin lymphoma (NCT02384954). The gene discussed is IL15; the disease is B-cell non-Hodgkin lymphoma.